Perfuze is a medical technology startup founded in 2018 by Wayne Allen and Liam Mullins, based in Galway City, Ireland. The company focuses on developing innovative solutions to treat acute ischemic stroke, a condition where blood flow to the brain is blocked, leading to severe health consequences. The founders bring over 30 years of combined experience in the medical technology sector, having worked in both startups and large corporations.

Perfuze operates in the healthcare and medical technology market, specifically targeting the treatment of stroke, which is the second most common cause of death worldwide and a leading cause of adult disability. The company's primary clients are healthcare providers, including hospitals and specialized stroke treatment centers, that require advanced medical devices to improve patient outcomes.

The business model of Perfuze revolves around the development, manufacturing, and sale of its proprietary medical devices designed to treat acute ischemic stroke. By providing innovative and effective treatment options, Perfuze aims to enhance the quality of care for stroke patients and reduce the long-term impacts of the condition.

Perfuze generates revenue through the sale of its medical devices to healthcare institutions. Additionally, the company may engage in partnerships or collaborations with other medical technology firms and healthcare providers to expand its market reach and enhance its product offerings.

In summary, Perfuze is a promising startup in the medical technology sector, dedicated to improving the treatment of acute ischemic stroke through innovative solutions. With a strong foundation of experienced founders and a clear focus on addressing a critical healthcare need, Perfuze is well-positioned to make a significant impact in the market.

Keywords: medical technology, acute ischemic stroke, healthcare, innovation, treatment, startup, Galway, Ireland, medtech, patient outcomes.